MIRA Pharmaceuticals has progressed its two lead preclinical drug candidates, MIRA-55 for chronic inflammatory pain and SKNY-1 for obesity and addiction disorders, through key development stages including formulation optimization, manufacturing, and exploratory toxicology studies. These milestones support moving both candidates toward IND-enabling studies, a critical step before clinical trials. MIRA-55 targets non-opioid pain relief with anti-inflammatory effects, while SKNY-1 shows promise in reducing body weight and addictive behaviors without anxiety side effects. The company aims to continue advancing these oral therapies to address significant unmet medical needs.
Frank Patton and Kimberlee Mott, financial advisors with 45 years of combined experience managing about $150 million in assets, have joined Balmville Wealth Group through LPL Financial. They bring a focus on retirement planning and multigenerational ...
Crescent Biopharma announced its second quarter 2026 financial results, highlighting progress in clinical trials for its cancer therapies, including CR-001, a PD-1 x VEGF bispecific antibody, and ADC candidates CR-002 and CR-003. The company is enrol...
Ferrari reported Q2 2026 net revenues of €1.94 billion, up 8% year-on-year, driven by a richer product mix and increased personalization sales. Operating profit rose 10% to €605 million with a margin of 31.2%, while net profit grew 9% to €463 million...
Purepoint Uranium Group announced results from the first phase of its 2026 summer drilling program at the Dorado Project in Saskatchewan, Canada. The highlight was drill hole NV26-11 at the Nova Discovery, which intersected 5.6 meters of continuous r...
United Maritime Corporation reported a net income of $1.2 million for Q2 2026, up from $1.0 million in Q2 2025, driven by strategic fleet repositioning into higher-earning Capesize vessels. The company generated $17.9 million in net revenues for the ...
